Evidence map›Paper›PMID 36797611›Full record

ArticleCurrent neuropharmacology2023

Selecting the Best Animal Model of Parkinson's Disease for Your Research Purpose: Insight from

Caroline Cristiano Real, Karina Henrique Binda, Majken Borup Thomsen, Thea Pinholt Lillethorup, David James Brooks, Anne Marlene Landau

Abstract read
In one paragraph

Article in Current neuropharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Research models to study lewy body dementia.Molecular neurodegeneration · 2025
    Review
  5. Review
  6. Positron emission tomography neuroimaging of [Frontiers in neuroscience · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Caroline Cristiano RealDepartment of Nuclear Medicine and PET Center, Aarhus University Hospital, Aarhus, Denmark.
Karina Henrique BindaDepartment of Nuclear Medicine and PET Center, Aarhus University Hospital, Aarhus, Denmark.
Majken Borup ThomsenDepartment of Nuclear Medicine and PET Center, Aarhus University Hospital, Aarhus, Denmark.
Thea Pinholt LillethorupDepartment of Nuclear Medicine and PET Center, Aarhus University Hospital, Aarhus, Denmark.
David James BrooksDepartment of Nuclear Medicine and PET Center, Aarhus University Hospital, Aarhus, Denmark.
Anne Marlene LandauDepartment of Nuclear Medicine and PET Center, Aarhus University Hospital, Aarhus, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a debilitating neurodegenerative multisystem disorder leading to motor and non-motor symptoms in millions of individuals. Despite intense research, there is still no cure, and early disease biomarkers are lacking. Animal models of PD have been inspired by basic elements of its pathogenesis, such as dopamine dysfunction, alpha-synuclein accumulation, neuroinflammation and disruption of protein degradation, and these have been crucial for a deeper understanding of the mechanisms of pathology, the identification of biomarkers, and evaluation of novel therapies. Imaging biomarkers are non-invasive tools to assess disease progression and response to therapies; their discovery and validation have been an active field of translational research. Here, we highlight different considerations of animal models of PD that can be applied to future research, in terms of their suitability to answer different research questions. We provide the reader with important considerations of the best choice of model to use based on the disease features of each model, including issues related to different species. In addition, positron emission tomography studies conducted in PD animal models in the last 5 years are presented. With a variety of different species, interventions and genetic information, the choice of the most appropriate model to answer research questions can be daunting, especially since no single model recapitulates all aspects of this complex disorder. Appropriate animal models in conjunction with in vivo molecular imaging tools, if selected properly, can be a powerful combination for the assessment of novel therapies and developing tools for early diagnosis.

Indexed as

Parkinson Diseasealpha-SynucleinAnimalsBiomarkersDisease Models, AnimalDisease ProgressionPositron-Emission Tomographyalpha-SynucleinBiomarkersalpha-synucleinAnimal modelsautoradiographyminipignon-human primateParkinson’s diseasepositron emission tomographyrodent

Identifiers

PMID36797611
PMCPMC10286593

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.